Singapore Paincare Holdings Provides July 2026 Update on Subsidiary Winding-Up
Key Highlights from the Report
- The Board of Directors of Singapore Paincare Holdings Limited (“the Company”) has issued its monthly update regarding the ongoing creditors’ voluntary winding-up process of its 51.0% owned subsidiary, Dermatology & Laser Specialist Clinic Pte. Ltd. (“DLS”).
- This update follows earlier announcements made on 3 February, 26 February, 26 March, 27 April, 26 May, and 26 June 2026.
- The Company confirms that there have been no material developments in the winding-up process since the previous update issued on 26 June 2026.
- The Company has committed to continuing monthly updates and will provide further announcements if and when there are any significant developments.
Important Considerations for Shareholders
- No New Price-Sensitive Developments: As of this update, there are no new material events or changes in the status of the creditors’ voluntary winding-up of DLS that could affect the Group’s financial position, operations, or share value.
- Caution Advised: Shareholders are strongly advised to exercise caution when dealing in the Company’s securities and to refrain from taking any action that may be prejudicial to their interests based on the current announcement.
- Consultation Recommended: In case of doubt, shareholders should seek advice from their stockbrokers, bank managers, solicitors, accountants, or other professional advisers.
Further Announcements
The Company reiterates its commitment to transparency and will continue to provide shareholders with monthly updates in accordance with Catalist Rule 704(22). Any material developments that could potentially impact the Company’s financial status or share price will be disclosed promptly.
Additional Information
- This announcement was issued by Lee Mun Kam Bernard, Executive Chairman and Chief Executive Officer, on 28 July 2026.
- The Company’s sponsor, Novus Corporate Finance Pte. Ltd., has reviewed this announcement. However, the Singapore Exchange Securities Trading Limited (SGX-ST) has neither examined nor approved the contents and assumes no responsibility for its accuracy.
- For further queries, shareholders can contact Mr. Pong Chen Yih, Chief Operating Officer at Novus, via phone at (65) 6950 2188.
Potential Impact on Share Price
Based on the information disclosed in this update, there are no new developments that are likely to have a direct impact on the Company’s share price at this time. The situation remains unchanged since the last update, and shareholders are advised to closely monitor future announcements for any significant changes.
Disclaimer
This article is provided for informational purposes only and does not constitute investment advice. Investors are urged to conduct their own research or consult professional advisors before making investment decisions.
新加坡疼痛护理控股有限公司发布2026年7月子公司清盘进展更新
报告要点
- 新加坡疼痛护理控股有限公司（“公司”）董事会发布了关于其持有51.0%股权的子公司Dermatology & Laser Specialist Clinic Pte. Ltd.（“DLS”）债权人自愿清盘进展的月度更新。
- 本次更新继2026年2月3日、2月26日、3月26日、4月27日、5月26日和6月26日的公告之后发布。
- 公司确认，自2026年6月26日上一次更新以来，清盘事项没有实质性进展。
- 公司将继续每月更新，如有任何重大进展将及时公告。
股东需关注的重要事项
- 无新的价格敏感事件： 截至本次更新，关于DLS清盘事项没有新的重大进展或变化，不会对集团的财务状况、运营或股价产生直接影响。
- 谨慎操作： 公司强烈建议股东在买卖公司证券时保持谨慎，不要因本次公告而做出对自身利益不利的操作。
- 建议咨询专业人士： 如有疑问，建议股东咨询股票经纪人、银行经理、律师、会计师或其他专业顾问。
后续公告
公司重申将秉持透明原则，按照Catalist Rule 704(22)每月向股东提供进展更新。如有任何可能影响公司财务状况或股价的重大事项，会第一时间公告。
其他信息
- 本公告由李文锦（Lee Mun Kam Bernard），公司执行主席兼首席执行官于2026年7月28日发布。
- 公司保荐人Novus Corporate Finance Pte. Ltd.已审阅本公告，但新加坡证券交易所有限公司（SGX-ST）未审查或批准公告内容，对其中任何陈述、意见或报告的准确性不承担责任。
- 如有疑问，可致电(65) 6950 2188联系Novus首席运营官Pong Chen Yih先生。
对股价的潜在影响
根据本次公告披露的信息，暂无新进展可能直接影响公司股价。清盘事项自上次公告以来未有变动，股东请持续关注后续公告。
免责声明
本文仅供参考，不构成投资建议。投资者应自行调研或咨询专业人士后作出投资决策。
